Bevacizumab regulates inflammatory cytokines and inhibits VEGFR2 signaling pathway in an ovalbumin-induced rat model of airway hypersensitivity.

Seyed Mohammadreza BolandiZohreh AbdolmalekiMohammad-Ali Assarehzadegan

Published in: Inflammopharmacology (2021)

The results show that bevacizumab efficiently diminishes bronchial inflammation via reducing the expression of VEGFR2, and IL-6 genes and enhancing the expression of IL-10 gene. Hence, bevacizumab could be considered as a potential candidate drug to control pathological conditions relevant to airway hypersensitivity.

Keyphrases

drug induced
poor prognosis
metastatic colorectal cancer
signaling pathway
genome wide
vascular endothelial growth factor
genome wide identification
high glucose
binding protein
diabetic rats
emergency department
gene expression
climate change
cell proliferation
induced apoptosis
human health
endothelial cells